AstraZeneca stock gains as Enhertu expands in England
Published on 09/22/2026 at 14:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock traded at GBP 125.68 in London on September 22, 2026, with the shares 25.16 percent below their 52-week high of GBP 157.30. The latest catalyst is wider access for Enhertu in England, while first-half sales show that the oncology franchise already has substantial scale.
Enhertu gains NHS access
As Yahoo Finance reported on September 22, 2026, AstraZeneca and Daiichi Sankyo's Enhertu was approved for use by England's National Health Service in patients with HER2-low metastatic breast cancer. The decision reverses an earlier cost-effectiveness rejection and expands access in a major European market.
The commercial comparison is already meaningful. Enhertu generated USD 1.72 billion of AstraZeneca revenue in the first half of 2026, while combined sales reported by the partners reached USD 2.96 billion, up 29 percent from USD 2.29 billion in the first half of 2025, according to Yahoo Finance.
Revenue keeps growing
AstraZeneca reported revenue of GBP 11.46 billion for the latest quarter cited on September 22, 2026, compared with GBP 10.83 billion in the year-earlier quarter. That represents growth of 5.84 percent, according to Finanzen.
The broader pipeline also supplied dated operating signals. The European Medicines Agency's CHMP issued positive opinions for Enhertu and Klygefa, while the FDA granted priority review to efzimfotase alfa, as MarketBeat reported on September 22, 2026.
Stock remains below its high
On the London market, the shares reached GBP 126.06 at the open and traded as low as GBP 125.62 during the September 22, 2026 session. The 52-week range extends from GBP 107.84 to GBP 157.30, leaving the stock closer to its low than its high on the quoted intraday data.
The valuation debate remains tied to growth investment and deal execution. Reuters Breakingviews wrote on September 22, 2026, that more than USD 40 billion had been wiped from AstraZeneca and Novartis in recent weeks as investors questioned their merger and acquisition strategies. That counter-factor makes the 5.84 percent quarterly revenue increase and the 29 percent year-on-year growth in combined Enhertu sales important, but not sufficient on their own to resolve the market's concerns.
London price stays measured
AstraZeneca stock stood at GBP 125.68 in London on September 22, 2026. The price was 25.16 percent below the 52-week high of GBP 157.30 and 16.55 percent above the 52-week low of GBP 107.84.
AstraZeneca stock at a glance
- Company: AstraZeneca plc
- ISIN: GB0009895292
- Ticker: AZN
- Trading venue: London Stock Exchange
- Price as of September 22, 2026: GBP 125.68
- 52-week range: GBP 107.84 to GBP 157.30
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: FTSE 100
